New triple therapy aims to tame immune side effects in advanced melanoma

NCT ID NCT03999749

Ongoing Disease control Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

First seen Mar 28, 2026 · Last updated May 24, 2026 · Updated 6 times

Summary

This phase 2 trial tests whether adding tocilizumab to standard immunotherapy (ipilimumab and nivolumab) can reduce severe immune-related side effects in people with advanced melanoma that cannot be removed by surgery. About 71 participants will receive the three drugs during an induction phase, followed by maintenance nivolumab alone for up to one year. The study measures safety, tumor response, and disease control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
NYU Langone Health

New York, New York, 10016, United States
The Angeles Clinic

Los Angeles, California, 90025, United States

Conditions

Explore the condition pages connected to this study.

MELANOMA